The largest database of trusted experimental protocols

15 protocols using fk506

1

Preparation of Bioactive Lipid Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
All activators and inhibitors were of analytical grade and freshly prepared from frozen stock solution. The stock solution of LPA was 5 mM dissolved in phosphate-buffered saline (PBS, Sigma-Aldrich, St. Louis, MO, USA). Pertussis toxin (PTX, Sigma-Aldrich) was dissolved at a concentration of 250 µg/mL in H2O. U0126 as well as Wortmannin (both Sigma-Aldrich) were dissolved at 10 mM in DMSO (Roth, Karlsruhe, Germany). Gö6976 (Tocris Biosciences, Bristol, UK) was dissolved at 1 mM in DMSO and ω-agatoxin-TK (Peptanova, Sandhausen, Germany) at 100 µM in H2O. For AlF4, 30 µM AlCl3 and 10 mM NaF were mixed. FK506 (InvivoGen, Toulouse, France) was dissolved at 20 mM in DMSO and Cyclosporin A (Alfa Aesar, Ward Hill, MA, USA) at 1 mM in ethanol.
+ Open protocol
+ Expand
2

Isolation and Activation of CD4 T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4 cells were isolated from spleen and lymph nodes by negative selection as previously described (Diehl et al., 2002 (link)). For Stat3+/+ and Stat3−/− mice, CD4 cells were purified by cell sorting (FACS-Aria; Becton Dickinson). CD4 cells were activated with plate-bound anti-CD3 (2C11) (5 μg/ml) and soluble anti-CD28 (1 μg/ml) (BD Pharmingen, San Diego, CA) mAbs in the presence or absence of IL-6 (50 ng/mL) (Miltenyi Biotec, Auburn, CA). Pharmacological inhibitors were added to culture 42 hr after activation and supernatants were harvested 6 hr later. APCs were purified by depleting CD4 and CD8 T cells using positive selection (Miltenyi), and followed by irradiation treatment (2000 rad). APCs and OT-II CD4 cells were co-cultured at 4:1 ratio in the presence of 5 μM OVA323-339 peptide (Barnden et al., 1998 (link)) with or without IL-6 (50 ng /mL) (Miltenyi) or anti-IL-6 (2.5 μg /mL) (BD Pharmingen).
Pharmacological inhibitors used were CGP-37157 (Tocris Bioscience, Ellisville, MO) (10 μM), CCCP (2 μM), rotenone (2 μM), antimycin (2 μM), Ru360 (10 μM), FK506 (InvivoGen, San Diego, CA) (10 nM), Stattic (10 μM).
+ Open protocol
+ Expand
3

Preparation of Stock Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Stock solutions of Calyculin A (1 mM, LC Labs), and FK506 (40 mM, Invivogen) were prepared in DMSO. The final concentration of DMSO in ACSF was less than 0.1%. Stock solutions of caged MNI-glutamate (80 mM, Tocris), D, L-APV (20 mM, Sigma), and TTX (2 mM, Abcom Biochemicals) were prepared in deionized water. All stocks were kept frozen at −80C0° in aliquots until use.
+ Open protocol
+ Expand
4

Fungal Strain Cultivation and Chemical Compound Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fungal strains were routinely grown in Yeast Extract Peptone Dextrose (YPD) medium (1% yeast extract, 2% peptone, 2% glucose), from cryopreserved cultures stored at −80 °C in 25% glycerol. Cyclosporin A (CsA; Cayman Chemical Company 12088-100), FK506 (Invivogen, tlrl-fk5), MGX (Amplyx Pharmaceuticals Inc.), and APX2039 (Amplyx Pharmaceuticals Inc.) stocks were prepared in DMSO at 10 mM. Chemical structures are summarized in Figure S1. Doxycycline hydrochloride (DOX; Bio Basic Canada) and propidium iodide (Millipore Sigma) stocks were prepared at 50 mg/mL in water and filter sterilized.
+ Open protocol
+ Expand
5

Modulating CD8+ T Cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols
C57BL/6 WT were treated by i.p. injection with anti-CD137 (10 μg; 3H3, BioXcell, twice a week) or control IgG (HRPN, BioXcell), and were treated daily with FK506 (invivogen, i.p. injection 3 mg/kg) or with cyclosporine A (invivogen, oral gavage, 28 mg/kg). Mice were sacrificed at day 14, and CD8+ T cells from spleen were prepared for phenotypical analyses.
+ Open protocol
+ Expand
6

Isolation and Characterization of ADSC-derived Exosomes

Check if the same lab product or an alternative is used in the 5 most similar protocols
ADSCs were purchased from iXCells Biotechnologies (MADSC-bf, San Diego, CA, USA). The ADSCs were from the interscapular brown fat tissue of C57BL/6 mice. These cells were expanded for subsequent passages using ADSC basal medium (Cat # MD-0003) under the protocol, according to instructions provided by iXcells Biotechnologies. The cells previously tested positive for stem cell markers CD105, CD73, CD90, CD44, and negative for CD3, CD11b, CD25, CD45, and CD106 by flow cytometry analysis. The exosomes secreted by ADSCs (ADSC-exo), as well as ADSCs treated with 100 µg/mL FK506 (InvivoGen, Hong Kong, China) in dimethyl sulfoxide (DMSO) for 24 h (ADSC-F-exo), were isolated for further animal experiments.
+ Open protocol
+ Expand
7

Cell Viability Assay of Leukemia Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
We analyzed cell viability and proliferation with the Cell Proliferation Kit I (Roche) after treating HH, HUT78, HUT102 and SeAX cell lines for 72 hours with a range of concentration of specific compounds. Ruxotilinib was kindly provided by Dr. Ross Levine. Tofacitinib, Mi-2 and Bortezomib were obtained from Shelleck Chemicals. U0126 was purchased from Sigma-Aldrich and FK506 from Invivogen.
+ Open protocol
+ Expand
8

Acute Cyclosporin-A and FK506 Effects

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cyclosporin-A (CsA, Sigma Aldrich) or FK506 (InvivoGen) were dissolved in DMSO to a final concentration of 20 mM. The feeding solution included 5% yeast and 5% sucrose in water. Adult males less than 1 day old were starved for 6 hours and then transferred to a vial containing a strip of Wattman paper soaked in feeding solution containing the designated concentration of CsA/FK506 or DMSO as control. Flies were behaviorally tested following 6, 12 or 24 hours of drug feeding.
+ Open protocol
+ Expand
9

Antibodies and Reagents for Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
We purchased the anti-GAL4 DNA binding domain (GAL4 DBD) (RK5C1) antibody from Santa Cruz Biotechnology (Dallas, TX, USA) and anti-NFATC2, pan-CNA, and phospho-MAPK Substrates Motif [PXpTP] antibodies from Cell Signaling (Danvers, MA, USA). We purchased anti-β-actin (AC-15) and Flag (M2) antibodies and Anti-FLAG ® M2 Affinity Gel from Sigma–Aldrich (St. Louis, MO, USA). We obtained the anti-HA (16B12) antibody from BioLegend (San Diego, CA, USA) and Pierce™ Anti-HA Agarose from Thermo Fisher Scientific. We acquired phorbol myristate acetate (PMA) and ionomycin from Sigma–Aldrich, FK506 from InvivoGen (San Diego, CA, USA), and EO 1428 and TAK 715 from Tocris (Bristol, UK).
+ Open protocol
+ Expand
10

Inhibition of MEK1/2 Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
MEK-1/2 inhibitor PD0325901 obtained from InvivoGen (Toulouse, France) and U0126 obtained from Sigma (Sigma-Aldrich, Lyon, France) were used as recommended by supplier. PD0325901 is a selective non-ATP-competitive allosteric MEK1/2 inhibitor with in vitro IC50 0.33 nM, which was shown to be specific against a panel of 70 different kinases at 10 µM range (54 (link)). U0126 inhibits MEK 1/2 with an in vitro IC50 of 0.5 µM. JNK inhibitor SP600125, TBK1 inhibitor BX795, NF-ĸB inhibitor Bay11-7082, p38 MAPK inhibitor SB253080, and calcineurin inhibitor FK506 were all purchased from InvivoGen, San Diego, USA. For in vitro pDC stimulation assays, CpG-A (ODN 2216), CpG-B (ODN 2006), and PMA (all InvivoGen, San Diego, USA), and BDCA-2 antibody (Miltenyi Biotech, Paris, France), and ILT7 antibody (eBioscience) were used.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!